Tez M. Charged multivesicular body protein 7 as a prognostic biomarker in colorectal cancer metastasis. World J Clin Oncol 2025; 16(10): 110056 [DOI: 10.5306/wjco.v16.i10.110056]
Corresponding Author of This Article
Mesut Tez, Professor, Department of Surgery, University of Health Sciences, Ankara City Hospital, No. 1 Bilkent Street, District of Universities, Ankara 06800, Türkiye. mesuttez@yahoo.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 24, 2025 (publication date) through Oct 27, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tez M. Charged multivesicular body protein 7 as a prognostic biomarker in colorectal cancer metastasis. World J Clin Oncol 2025; 16(10): 110056 [DOI: 10.5306/wjco.v16.i10.110056]
World J Clin Oncol. Oct 24, 2025; 16(10): 110056 Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110056
Charged multivesicular body protein 7 as a prognostic biomarker in colorectal cancer metastasis
Mesut Tez
Mesut Tez, Department of Surgery, University of Health Sciences, Ankara City Hospital, Ankara 06800, Türkiye
Author contributions: Tez M wrote the manuscript, and read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The author has no conflicts of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mesut Tez, Professor, Department of Surgery, University of Health Sciences, Ankara City Hospital, No. 1 Bilkent Street, District of Universities, Ankara 06800, Türkiye. mesuttez@yahoo.com
Received: May 28, 2025 Revised: June 5, 2025 Accepted: July 17, 2025 Published online: October 24, 2025 Processing time: 148 Days and 22.9 Hours
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality, primarily due to tumor metastasis. A recent study in the World Journal of Gastrointestinal Oncology identifies charged multivesicular body protein 7 (CHMP7) as a key prognostic factor in CRC. The study showed that CHMP7 expression is significantly lower in patients with CRC with metastasis and in highly metastatic cell lines, correlating with clinical factors like normal tissue, metastatic tumors, pathologic stage, and lymphatic invasion. Higher CHMP7 expression was linked to improved overall survival, highlighting its potential as a predictive biomarker. Gene Set Enrichment Analysis also suggests the role of CHMP7 in metastasis-related pathways, paving the way for further mechanistic studies. This finding challenges current CRC management strategies and calls for larger, prospective studies to validate the role of CHMP7. As a potential target for novel diagnostics and therapies, CHMP7 could advance personalized medicine in CRC, bridging molecular insights with clinical outcomes to improve patient prognosis.
Core Tip: The downregulation of charged multivesicular body protein 7 in colorectal cancer (CRC) is linked to metastasis and poor prognosis, with roles in micronuclear collapse, organelle membrane contact sites, genomic stability, Wnt signaling, and tumor microenvironment modulation. Its prognostic significance across cancers highlights its potential for targeted CRC therapies.
